HR Strategy & Policy, Acquisitions, Change Mgt Advocate for @Becstroops, #AYA Cancer, #KidneyCancer, #clinicaltrials Chair Consumer Advisory Panel @ANZUPtrials
Melbourne
Joined September 2013
- Tweets394
- Following535
- Followers210
- Likes1.4K
Pinned Tweet
Oct is @ANZUPtrials 111 #yourway mth. I will do 111 sit-ups/crunches daily. Aim to raise $111 per day. 111 represents the no. of #belowthebelt cancers diagnosed in Aus & NZ each day funds raised support #clinicaltrial research. My full story & donations 🙏 belowthebelt111yourway.org.a…
Belinda Jago retweeted
Twice today already at ASCO I have heard presenters say “patients failed treatment”.
Can we please, please stop that?
Treatments fail patients, not the other way around…
Belinda Jago retweeted
Sometimes it’s better to know what not to do. That brings the whole world along, whereas a “+ve” trial is sometimes only a small step forward and not in practice until a long time after. Maybe time to retire the term “negative” and look instead at the effect on the whole field.
Belinda Jago retweeted
Welcome to 2026!
A little morning cloud on and south of the ranges, then a mostly sunny day throughout. Cool to mild in the south, warm in the north. SE winds. bom.gov.au/location/australi…
Belinda Jago retweeted
First @ANZUPtrials Ideas Generation Workshop in New Zealand - putting the NZ into ANZUP! Thanks to @nickymitchell and @DrCraigGedye for the warm welcome.
Belinda Jago retweeted
Correlative work is possibly our most important tool in clinical trials. Congrats to @EdmondMKwan & #TheraP team for this insightful pub on ctDNA burden & PTEN loss predicting responses to 177Lu-PSMA & reminding us of his why - the patients behind the data. @ANZUPtrials #ANZUP25
Belinda Jago retweeted
@oncology_bg gives an engaging, hilarious, and deeply thought-provoking talk on common sense communication in @ANZUPtrials #ANZUP25 opening plenary session on “Connecting with big ideas.”
Great day was had by the @ANZUPtrials Consumer Advisory Panel and guests attending our annual education day #ANZUP25 . Always a special day, meeting face to face instead of zoom. #consumer #engagement #clinicaltrials @Prof_IanD @SamanthaROakes
#BTBcancers
Belinda Jago retweeted
The #ANZUP25 ASM kicks off this Sunday!
Insightful sessions, expert speakers, and plenty of opportunity to connect with your GU peers.
Check your inbox to make sure you've downloaded the app to explore the program, plan your agenda, and stay updated. #listenreflectconnect
Belinda Jago retweeted
📣 The ANZUP 2024/25 Annual Report is now live!
Explore key research milestones, clinical innovations, and the impact we’re making together.
📖 Read the full report: bit.ly/ANZUP_AR25
Belinda Jago retweeted
🚨 Late-breaker at #ASCO25!
Dr. Dickon Hayne presents LBA4504 – ANZUP 1301 trial
💥 Mitomycin + BCG vs BCG alone in high-risk NMIBC
➡️ Phase 3 results could change the game in bladder-sparing therapy!
#BladderCancer #UroOnc #ASCO2025
Watch Here -> tinyurl.com/y5uek8yw – at Chicago, IL
Belinda Jago retweeted
Congrats @ANZUPTrials #TheraP study presented #ASCO25 by Dr Aslı Munzur. Thanks to @PCFnews @bccancerfdn @TerryFoxCanada #CanadianCancerSociety @PeterMacCC @pros_tic @VanProstateCtr @VCHResearch @UBC @PCFA @MovemberAUS @ANSTO @adacap_news @TrialsCentre @gentlemansride @Novartis
Clonal hematopoiesis (CH) in the @ANZUPtrials #TheraP study @ASCO #ASCO25 presented by Asli Munzur
■ ¹⁷⁷Lu-PSMA-617: higher incidence of emergent CH compared to cabazitaxel chemotherapy
■ Most new clonal hematopoiesis mutations ¹⁷⁷Lu-PSMA-617 fall in DNA damage repair response genes PPM1D, TP53, ATM, and CHEK2.
■ Clinical significance unclear but may become more relevant as radioligand therapy moves into earlier lines of treatment
@ResearchWyatt @AzadOncology
Belinda Jago retweeted
Congrats to our @ANZUPTrials #EVOLUTIONtrial for on their oral presentation by @SandhuShahneen @ASCO25. This Phase 2 #ProstateCancer trial is supported by @PCFA and collaborators @TrialsCentre @bmsnews @Novartis Thanks Study Co-Chair @drlouiseemmett & @CancerAustralia @Prof_IanD
@ANZUPtrials #EVOLUTION trial live at @ASCO #GU25
¹⁷⁷Lu-PSMA-617 + ipilimumab (n=67) + nivolumab vs. ¹⁷⁷Lu-PSMA-617 (n=33)
■ rPFS favouring ¹⁷⁷Lu immunotherapy: HR 0.53 (95% CI 0.32-0.90)
■ PSA-50 RR 75% vs. 67%
■ Grade 3-4 AEs 76% vs. 29%
@SandhuShahneen @drlouiseemmett
Belinda Jago retweeted
Well done! The @ANZUPTrials #BCGMM trial has been presented @ASCO25 showing BCG plus mitomycin a safe & effective alternative to BCG alone & the added benefit of requiring 40% fewer BCG doses. Congrats to Prof Dickon Hayne & team @Prof_IanD @TrialsCentre @MSD_Aus #OmegaPharm
@ANZUPtrials rand PhIII ANZUP 1301 of intravesical MMC + BCG vs BCG in tx-naive #HR-NMIBC ➡️ no sig diff in DFS, time to recurrence or progression, or OS between arms. Post-hoc suggests MMC
addition may benefit in higher-risk (all T1, CIS) subgroup
#ASCO25
@OncoAlert
Belinda Jago retweeted
#BCGMM presented by Dickon Hayne at #ASCO25. Simple question, hard trial, needed a cooperative group like @ANZUPtrials @TrialsCentre. Discussant @DrJohnSfakianos v enthusiastic, one of the most impactful #NMIBC trials he has seen, will change his practice. #BladderCancer #blcsm
Belinda Jago retweeted
📢 #ASCO25 | ANZUP 1301 Ph III | HR NMIBC (~500 pts): Mitomycin + BCG vs BCG alone—combination arm met primary endpoint with significant DFS benefit (HR 0.70; 2‑yr DFS 78% vs 65%); recurrence reduced. Dickon Hayne et al. Full abstract → asco.org/abstracts-presentat…
@ASCO @ASCOPost @JCO_ASCO @neerajaiims @montypal @bergsa83 @GlopesMd @VivekSubbiah @OncoAlert @tompowles1 @OncBrothers @medicalwatchBC @yekeduz_emre @CParkMD @Silke_Gillessen @PGrivasMDPhD @TwoOncDocs @OncBrothers @Larvol @nataliagandur @crisbergerot @DrDanielHeng @TiansterZhang @HammersMD @sonpavde @drenriquegrande @scserendipity1 @BraunMDPhD @Uromigos @AminNassarMD @ZiadBakouny @DrRanaMcKay @NazliDizman
Belinda Jago retweeted
Tour de force of investigator initiated trial across @ANZUPtrials - really important practical question of BCG+mitomycin efficacy for non-muscle invasive #bladdercancer. @ASCO #ASCO25 @OncoAlert @urotoday
#ANZUP1301 phase III showed similar efficacy/safety of #BCG+#mitomycin v. BCG in high risk #NMIBC (pTa/pT1)- fewer tx discontinuations and fewer doses of BCG (by 40%) in the combo arm, making it a possible alternative particularly in the context of global BCG shortage #ASCO25
Belinda Jago retweeted
Just had a great conversation with Dickon Hayne FRCS, MD, MBBS, of @RaineFoundation about updated data from the ANZUP study of mitomycin plus BCG as adjuvant intravesical therapy in high-risk NMIBC. Be sure to visit onclive.com to learn more! @ANZUPtrials @ASCO #blcsm
Belinda Jago retweeted
Our 2025 @ANZUPTrials #KidneyCancer Masterclass is underway. Thanks to Co-Convenors @DrL_Krieger & @doccharris & our many great speakers, attendees & sponsors Eisai (Platinum) & Ipsen & MSD (Supporters) @CancerAustralia @Prof_IanD
Belinda Jago retweeted
Below the Belt Research Fund Grant applications are officially open! All necessary information and important details can be found on our website - ow.ly/jva450Vvlmo
Belinda Jago retweeted
April is #TesticularCancerAwarenessMonth – a time to recognise the prevalence of this Below the Belt cancer and the incredible people working to improve outcomes.
Their dedication is driving better treatments, improving patient care, and bringing hope to those affected.💙👏
